Accelerate Diagnostics reports Q3 2018 financial results
Nov 06, 2018
Revenue Placements up 40 Percent in U.S., Total Revenue up 64 Percent
TUCSON, Ariz., Nov. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending September 30, 2018. The company reported a 40% increase in U.S. instruments placed under commercial contract, and revenue for the quarter of $1.3 million, an increase of 64% from the prior year quarter. Worldwide, revenue-generating instruments combined with those under evaluation agreements grew to 458 instruments.
- Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results
Jan 13, 2020
- Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes
Oct 03, 2019